PLASMA Trial: A Dose-Response Study of A-002 In Subjects With Stable Coronary Artery Disease
Status:
Completed
Trial end date:
2007-09-01
Target enrollment:
Participant gender:
Summary
The study will be conducted at up to 80 centers worldwide and will be a double-blind
randomized parallel group placebo controlled study among subjects with stable coronary artery
disease (CAD). Subjects will be randomized to receive either placebo tablets or one of 4
orally active doses of A-002. The duration of study drug therapy will be 8 weeks.